The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy
Abstract
AIMS: The CHA(2)DS(2)-VASc score is a modification of the CHADS(2) score that aims to improve stroke risk prediction in patients with atrial fibrillation (AF) by adding three risk factors: age 65-74, female sex, and history of vascular disease. Whereas previous evaluations of the CHA(2)DS(2)-VASc score included all AF patients, the aim of this analysis was to evaluate its discriminative ability only in those patients for whom recommendations on antithrombotic treatment are uncertain (i.e. CHADS(2) score of 1). METHODS AND RESULTS: We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score. Of 4670 patients with a baseline CHADS(2) score of 1, 26% had a CHA(2)DS(2)-VASc score of 1 and 74% had a score of ≥ 2. After 11 414 patient-years of follow-up, the annual incidence of SSE was 0.9% (95% CI: 0.6-1.3) and 2.1% (95% CI: 1.8-2.5) for patients with a CHA(2)DS(2)-VASc score of 1 and ≥ 2, respectively. The c-statistic of the CHA(2)DS(2)-VASc score was 0.587 (95% CI: 0.550-0.624). Age 65 to <75 years was the strongest of the three new risk factors in the CHA(2)DS(2)-VASc score. CONCLUSION: The CHA(2)DS(2)-VASc score reclassifies 26% of patients with a CHADS(2) score of 1 to a low annual risk of SSE of 1%. This risk seems low enough to consider withholding anticoagulant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Lip, G. Y. H., Nieuwlaat, R., Pisters, R., Lane, D. A., & Crijns, H. J. G. M. (2010) · Chest · doi:10.1378/chest.09-1584 · Cited by 6,879
Self-citationKearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805 · cited 1×
“The major strength of the present study is that the analysis is restricted to the group of patients for whom current guidelines provide conflicting recommendations.(5,6) Despite this restriction, this study included a large number of patients (n 1⁄4 4670) enrolled in large randomized trials with rigorous patient follo…”
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) was designed to determine the efficacy and safety of apixaban compared with ASA for the treatment of patients with AF for whom VKA therapy was considered unsuitable.(11) The ACTI…”
MethodEffect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102 · cited 2×
“The ACTIVE-W trial compared clopidogrel plus ASA with VKA therapy, and the ACTIVE-A trial compared clopidogrel plus ASA with ASA alone in patients for whom therapy with a VKA was considered unsuitable.(12,13) The inclusion criteria for the AVERROES and ACTIVE trials were similar and are described in detail elsewhere.”
BackgroundMethod(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952 · cited 2×
“The ACTIVE-W trial compared clopidogrel plus ASA with VKA therapy, and the ACTIVE-A trial compared clopidogrel plus ASA with ASA alone in patients for whom therapy with a VKA was considered unsuitable.(12,13) The inclusion criteria for the AVERROES and ACTIVE trials were similar and are described in detail elsewhere.”
BackgroundMethod
Cited by
Bushnell, C., McCullough, L. D., Awad, I. A., Chireau, M. V., Fedder, W. N., Furie, K. L., Howard, V. J., Lichtman, J. H., Lisabeth, L. D., Piña, I. L., et al. (2014) · Stroke · doi:10.1161/01.str.0000442009.06663.48 · Cited by 941
Stroke prevention in atrial fibrillation: An Asian perspective
Wang, K.-L., Lip, G. Y. H., & Chiang, C.-E. (2014) · Thrombosis and Haemostasis · doi:10.1160/th13-11-0948 · Cited by 287
Self-citationThromboembolic Complications After Cardioversion of Acute Atrial Fibrillation
Airaksinen, K. E. J., Grönberg, T., Nuotio, I., Nikkinen, M., Ylitalo, A., Biancari, F., & Hartikainen, J. E. K. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.089 · Cited by 258
“Interestingly, both of the recommended stroke risk scores (Congestive heart failure, Hypertension, Age 75, Diabetesmellitus, andprior Stroke or transient ischemic attack [doubled]; and Congestive heart failure, Hypertension, Age 75 [doubled], Diabetes mellitus, and prior Stroke, transient ischemic attack, or thromboem…”
BackgroundFriberg, L., Skeppholm, M., & Terént, A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.10.052 · Cited by 207
Metadata
- Authors
- Coppens, M., Eikelboom, J. W., Hart, R. G., Yusuf, S., Lip, G. Y. H., Dorian, P., Shestakovska, O., & Connolly, S. J.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-09-27
- Volume
- 34
- Issue
- 3
- Pages
- 170-176
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2165757837
- Cited by
- 184
- References
- 10
- FWCI
- 14.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. https://app.cochat.ai/papers/10.1093/eurheartj/ehs314
- The paper
- Coppens, M., Eikelboom, J. W., Hart, R. G., Yusuf, S., Lip, G. Y. H., Dorian, P., Shestakovska, O., & Connolly, S. J. (2013). The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. European Heart Journal. https://doi.org/10.1093/eurheartj/ehs314
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.